Evogene Ltd.
$0.8
▼
-3.11%
2026-04-21 06:44:00
www.evogene.com
NCM: EVGN
Explore Evogene Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.92 M
Current Price
$0.8
52W High / Low
$2.42 / $0.72
Stock P/E
—
Book Value
$-0.01
Dividend Yield
—
ROCE
-84.53%
ROE
-1.01%
Face Value
—
EPS
$-1.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.95
Debt / Equity
18.36
Current Ratio
4.54
Quick Ratio
4.48
Forward P/E
-1.01
Price / Sales
2.08
Enterprise Value
$9.32 M
EV / EBITDA
-0.7
EV / Revenue
2.42
Rating
None
Target Price
$1.75
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Gossamer Bio, Inc. | $0.42 | — | $98.57 M | — | -150.03% | 365.33% | $3.87 / $0.32 | $-0.53 |
| 2. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 3. | KalVista Pharmaceuticals, Inc. | $20.87 | — | $1.07 B | — | -89% | -121.5% | $21.3 / $9.83 | $-0.05 |
| 4. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 5. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 6. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 7. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.31 M | 0.31 M | 0.88 M | 2.44 M | 1.61 M | — |
| Operating Profit | -5.21 M | -2.72 M | -3.07 M | -4.13 M | -4.57 M | — |
| Net Profit | -5.31 M | 3.87 M | -4.46 M | -2.59 M | 0.43 M | — |
| EPS in Rs | -0.54 | 0.39 | -0.45 | -0.26 | 0.04 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.85 M | 5.58 M | 2.98 M | 1.68 M |
| Operating Profit | -14.03 M | -18.8 M | -22.23 M | -26.94 M |
| Net Profit | -8.48 M | -16.48 M | -23.88 M | -26.64 M |
| EPS in Rs | -0.86 | -1.67 | -2.41 | -2.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 20.05 M | 39.86 M | 51.1 M | 56.13 M |
| Total Liabilities | 8.07 M | 25.03 M | 22.42 M | 21.34 M |
| Equity | -0.08 M | -1.45 M | 12.05 M | 27.93 M |
| Current Assets | 15.63 M | 21.59 M | 34.47 M | 37.75 M |
| Current Liabilities | 3.44 M | 18.7 M | 6.94 M | 5.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.5 M | -19.7 M | -21.58 M | -23.68 M |
| Investing CF | 17.74 M | 9.62 M | -4.54 M | 13.27 M |
| Financing CF | -6.6 M | 4.66 M | 18.15 M | 9.34 M |
| Free CF | -13.64 M | -20.33 M | -22.15 M | -24.85 M |
| Capex | -0.14 M | -0.63 M | -0.58 M | -1.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -30.91% | 87.02% | 78.03% | — |
| Earnings Growth % | 48.53% | 30.96% | 10.36% | — |
| Profit Margin % | -220.22% | -295.59% | -800.77% | -1590.33% |
| Operating Margin % | -364.24% | -337.17% | -745.51% | -1608.42% |
| Gross Margin % | -6.25% | 57.32% | 50.03% | 45.73% |
| EBITDA Margin % | -316.56% | -239.63% | -688.53% | -1612.48% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-07-25 | 1:0.1 |